Given the evidence of the role that the adaptive and innate immune systems play in tauopathy and TBI, targeting mediators of the neuroinflammatory axis may be a potential therapeutic target for reducing p-tau and the progression of CTE. The gene discussed is MAPT; the disease is tauopathy.